TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY
Falchi L, Lue J, Montanari F, Marchi E, Amengual J, Sawas A, Deng C, Khan K, Kim H, Rada A, Malanga M, Francescone M, Soderquist C, Park D, Bhagat G, Sokol L, Shustov A, O'Connor O. TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY. Hematological Oncology 2019, 37: 178-179. DOI: 10.1002/hon.135_2629.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaClinical-molecular correlationsPhase 2 studyT-cell lymphomaLymphomaRomidepsinOral